(Q43107438)

English

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome

scientific article published in April 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Keith Lloyd

1

0 references

author name string

Muhammud A Latif

2

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Steve Simpson

3

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Keshar L Shrestha

4

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

publication date

1 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Human Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

243-252

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Long-acting risperidone: a review of its use in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

21 January 2018

Clinical review of a long-acting, injectable formulation of risperidone

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

21 January 2018

A systematic review of atypical antipsychotic drugs in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term depot antipsychotics. A risk-benefit assessment

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Depot antipsychotic drugs. Place in therapy

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of the SF-36 version 2 in the United Kingdom

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacologic treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Partial compliance and patient consequences in schizophrenia: our patients can do better.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Health resource utilization associated with switching to risperidone long-acting injection

1 reference

https://api.crossref.org/works/10.1002%2FHUP.1108

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HUP.1108

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

release_dzyvgl66wna7niv2l5jgd6auje

1 reference

https://api.fatcat.wiki/v0/release/dzyvgl66wna7niv2l5jgd6auje

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43107438&oldid=1980885911"